Key facts
- It has raised $19.8M across 1 recorded rounds; the latest was Mezzanine ($240K) in Nov 2024.
- Notable investors include National Institutes of Health, Keiretsu Forum, Band of Angels, Arizona Commerce Authority, Arizona Tech Investors — 19 tracked in total.
- NuvOx Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Nov 2024 ($235K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for NuvOx Therapeutics
Funding rounds
1 roundsAbout NuvOx Therapeutics
Developer of a pharmaceutical company designed to treat life-threatening diseases. The company's platform develops a drug that reverses hypoxia by increasing the amount of oxygen carried in the body and improves the flow of oxygen from the lungs to the blood and from blood to tissue, enabling medical practitioners to improve oxygen delivery in the bloodstream to help treat life-threatening conditions.
- Sector
- Healthcare
- HQ
- Tucson, AZ, United States
- Founded
- 2008
- Employees
- 13
- Website
- nuvoxtherapeutics.com/
- Ownership
- Privately Held (backing)
NuvOx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NuvOx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NuvOx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.